- PC14586 clinical program to be led by
Deepika Jalota , Pharm.D. (Chief Development Officer) andMarc Fellous , M.D. (Senior Vice President, Head of Clinical Development and Medical Affairs) Michael Carulli promoted to Chief Financial OfficerRobert Ticktin , General Counsel, will expand responsibilities to include management of OperationsTim Smith , Senior Vice President, Head of Corporate Development, will expand responsibilities to include Investor Relations- PC14586 registrational Phase 2 clinical trial remains on track to initiate in Q1 2024
- The PC14586 clinical program will be led by
Deepika Jalota , Pharm.D. andMarc Fellous , M.D. Dr. Jalota andDr. Fellous succeedLeila Alland , M.D., who is stepping down to pursue other opportunities.Dr. Alland will remain as an advisor to the company.Dr. Jalota joined PMV in 2019 and was promoted to Chief Development Officer (CDO) inMay 2023 .Dr. Fellous joined PMV in 2022 and was promoted to Senior Vice President, Clinical Development and Medical Affairs inMay 2023 . Michael Carulli has been promoted to Chief Financial Officer (CFO).Mr. Carulli succeedsWinston Kung , who is stepping down to pursue other opportunities.Mr. Kung will remain as an advisor to the company.Mr. Carulli joined PMV in 2020 as Vice President, Finance and was instrumental in the company’s initial public offering process.Mr. Carulli later assumed responsibility of all finance and accounting functions and was promoted to Senior Vice President, Finance inMarch 2023 .Robert Ticktin , General Counsel, will expand his responsibilities to include management of Human Resources, IT and Facilities.Tim Smith , Senior Vice President, Head of Corporate Development, will expand his responsibilities to include Investor Relations.
“We are fortunate to have a deep bench of experienced individuals to drive the development of PC14586. Deepika has proven to be one of the strongest CDOs in the industry with a track record of successful clinical development and drug approvals in oncology, including tumor agnostic drugs such as larotrectinib. Combined with Marc’s experience in global drug development and regulatory approvals, we are well positioned to drive PMV’s next phase of growth. I also want to congratulate Mike, Rob, and Tim in their new and expanded roles at PMV. Mike has been a leader of the finance organization and we are excited for him to step into the CFO role,” added
About PMV Pharma
PMV Pharma is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53. p53 mutations are found in approximately half of all cancers. The field of p53 biology was established by our co-founder Dr.
About PC14586
PC14586 is a first-in-class, small molecule, p53 reactivator designed to selectively bind to the pocket present in the p53 Y220C mutant protein, hence, restoring the wild-type, or normal, p53 protein structure and tumor-suppressing function. The
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the Company’s future plans or expectations for PC14586, including expectations regarding timing of the Phase 2 portion of its current clinical trial for PC14586 and advancement into late-stage development for PC14586, and statements regarding the Company’s expectations with respect to the leadership changes. Any forward-looking statements in this statement are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include: the success, cost, and timing of the Company’s product candidate development activities and planned clinical trials, the Company’s ability to execute on its strategy and operate as a late-stage development company, the potential for clinical trials of PC14586 or any future clinical trials of other product candidates to differ from preclinical, preliminary, interim or expected results, the Company’s ability to fund operations, and the impact that the current COVID-19 pandemic will have on the Company’s clinical trials, supply chain, and operations, as well as those risks and uncertainties set forth in the section entitled “Risk Factors” in the Company’s Annual Report on Form 10-K filed with the
Investors Contact:
Senior Vice President, Head of Corporate Development and Investor Relations
investors@pmvpharma.com
Media Contact:
kathy@greigcommunications.com
Source:
2024 GlobeNewswire, Inc., source